左炔诺孕酮宫内释放系统在子宫腺肌病中的应用(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨左炔诺孕酮宫内释放系统对子宫腺肌病患者临床症状的治疗效果。 方法 选取来我院就诊的子宫腺肌病患者39例，采用PBAC法及VRS法分别在左放置炔诺孕酮宫内释放系统之前、之后3、6、12个月时对患者的月经量及疼痛情况进行评分，并对患者的CA125、E2、FSH、LH进行测定。 结果 放置左炔诺孕酮宫内释放系统后3、6、12个月时患者的PBAC、VRS评分均较放置前明显降低，差异具有统计学意义(P < 0.05)；放置左炔诺孕酮宫内释放系统后3、6、12个月时患者CA125与放置前比较明显降低，差异具有统计学意义(P < 0.05)，而患者的E2、FSH、LH在放置前后无明显变化。 结论 对于子宫腺肌病患者给予左炔诺孕酮宫内释放系统有较好的治疗效果，能明显改善患者的月经过多和痛经等临床症状。
[关键词] 子宫腺肌病；左炔诺孕酮宫内释放系统；治疗效果
[中图分类号] R711.74 [文献标识码] B [文章编号] 1673-9701(2012)06-0053-02
The application of levonorgestrel releasing intrauterine system in adenomyosis
CHEN Yun
Department of Gynecology, Yuyao Second People's Hospital in Zhejiang Province, Yuyao 315400, China
[Abstract] Objective To investigate the clinical syndrome and effect of levonorgestrel releasing intrauterine system on patients with uterine adenomyosis. Methods All of 39 patients with adenomyosis were selected from our hospital were treated with levonorgestrel releasing intrauterine system. VRS and PBAC were used to evaluate the flow and pain of the patients before and after 3, 6, 12 by placing the levonorgestrel releasing intrauterine system, and the patient's CA125, E2 , FSH, LH were measured. Results The patient's PBAC, VRS scores of placing the levonorgestrel intrauterine release system after 6, 12 months were significantly lower than before, and the difference were statistically significant (P < 0.05). CA125 was obvious lower after 6, 12 months than before, and the difference was statistically significant (P < 0.05), while patients with E2, FSH, LH showed no significant change in placement. Conclusion Levonorgestrel releasing intrauterine system has a therapeutic effect on patients with adenomyosis, and can significantly improve the patient's menorrhagia and dysmenorrhea and other clinical symptoms.
[Key words] Adenomyosis; Levonorgestrel releasing intrauterine system; Treatment effect
子宫腺肌病为临床妇科较为常见的一种疾病，其临床主要症状为痛经及月经量过多。在子宫腺肌病治疗中，使患者的痛经得到明显缓解及使其月经量得到减少是治疗的主要目的[1]。采用传统的治疗方案治疗不能收到较为满意的治疗效果，并且存在着治疗停药后又出现较高的复发率的弊端，同时，治疗过程中往往存在着较多的不良反应使患者难以耐受，较高的治疗费用使患者承受困难等，以上原因均阻碍了药物治疗的顺利进行。新型的激素宫内避孕系统左炔诺孕酮宫内释放系统，引自国外，国内外关于其治疗方面的作用也有较多的报道。本研究选取2009～2011年来我院就诊的子宫腺肌病患者39例，采用左炔诺孕酮宫内释放系统进行治疗，效果较为满意，现报道分析如下。
1 资料与方法
1.1 一般资料
选取2009年10月～2011年10月来我院就诊的子宫腺肌病患者39例，均以月经过多及腹痛为主要的临床症状，疾病的诊断均以B超诊断结果并综合患者的临床症状及体征确诊 ......
您现在查看是摘要介绍页，详见PDF附件(2073kb)。